AXQ Capital LP Buys Shares of 13,732 REGENXBIO Inc. (NASDAQ:RGNX)

AXQ Capital LP purchased a new stake in REGENXBIO Inc. (NASDAQ:RGNX) during the 4th quarter, Holdings Channel reports. The firm purchased 13,732 shares of the biotechnology company’s stock, valued at approximately $106,000.

Other hedge funds also recently made changes to their positions in the company. Redmile Group LLC increased its position in REGENXBIO by 7.1% in the 3rd quarter. Redmile Group LLC now owns 4,892,902 shares of the biotechnology company’s stock valued at $51,327,000 after acquiring an additional 323,100 shares during the period. Geode Capital Management LLC increased its holdings in shares of REGENXBIO by 4.2% during the third quarter. Geode Capital Management LLC now owns 1,088,651 shares of the biotechnology company’s stock valued at $11,422,000 after purchasing an additional 44,037 shares during the period. Assenagon Asset Management S.A. raised its stake in shares of REGENXBIO by 53.0% during the fourth quarter. Assenagon Asset Management S.A. now owns 856,572 shares of the biotechnology company’s stock valued at $6,621,000 after purchasing an additional 296,700 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in REGENXBIO by 9.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 417,739 shares of the biotechnology company’s stock worth $4,382,000 after purchasing an additional 37,055 shares during the period. Finally, Hennion & Walsh Asset Management Inc. grew its position in REGENXBIO by 8.6% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 164,729 shares of the biotechnology company’s stock valued at $1,273,000 after buying an additional 13,014 shares in the last quarter. Institutional investors own 88.08% of the company’s stock.

REGENXBIO Stock Up 5.6 %

Shares of NASDAQ RGNX opened at $8.70 on Tuesday. REGENXBIO Inc. has a 12 month low of $5.62 and a 12 month high of $22.42. The company has a market cap of $435.75 million, a price-to-earnings ratio of -1.73 and a beta of 1.35. The business has a fifty day simple moving average of $7.34 and a 200-day simple moving average of $8.85.

REGENXBIO (NASDAQ:RGNX) last announced its earnings results on Thursday, March 13th. The biotechnology company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.27) by $0.26. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. The company had revenue of $21.21 million during the quarter, compared to analysts’ expectations of $23.70 million. As a group, sell-side analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Raymond James began coverage on shares of REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 price target on the stock. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, March 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 price target on shares of REGENXBIO in a research note on Tuesday, January 21st. The Goldman Sachs Group downgraded REGENXBIO from a “buy” rating to a “neutral” rating and dropped their price objective for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Finally, HC Wainwright lowered their target price on REGENXBIO from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, March 17th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $33.88.

REGENXBIO Company Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.